Liu, Y-L; Patman, G L; Leathart, J B S; Piguet, Anne Christine; Burt, A D; Dufour, Jean-François; Day, C P; Daly, A K; Reeves, H L; Anstee, Q M (2014). Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of hepatology, 61(1), pp. 75-81. Elsevier 10.1016/j.jhep.2014.02.030
Text
Carriage of the PNPLA3.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (658kB) |
BACKGROUND & AIMS
Subtle inter-patient genetic variation and environmental factors combine to determine disease progression in non-alcoholic fatty liver disease (NAFLD). Carriage of the PNPLA3 rs738409 c.444C >G minor allele (encoding the I148M variant) has been robustly associated with advanced NAFLD. Although most hepatocellular carcinoma (HCC) is related to chronic viral hepatitis or alcoholic liver disease, the incidence of NAFLD-related HCC is increasing. We examined whether rs738409 C >G was associated with HCC-risk in patients with NAFLD.
METHODS
PNPLA3 rs738409 genotype was determined by allelic discrimination in 100 European Caucasians with NAFLD-related HCC and 275 controls with histologically characterised NAFLD.
RESULTS
Genotype frequencies were significantly different between NAFLD-HCC cases (CC=28, CG=43, GG=29) and NAFLD-controls (CC=125, CG=117, GG=33) (p=0.0001). In multivariate analysis adjusted for age, gender, diabetes, BMI, and presence of cirrhosis, carriage of each copy of the rs738409 minor (G) allele conferred an additive risk for HCC (adjusted OR 2.26 [95% CI 1.23-4.14], p=0.0082), with GG homozygotes exhibiting a 5-fold [1.47-17.29], p=0.01 increased risk over CC. When compared to the UK general population (1958 British Birth Cohort, n=1476), the risk-effect was more pronounced (GC vs. CC: unadjusted OR 2.52 [1.55-4.10], p=0.0002; GG vs. CC: OR 12.19 [6.89-21.58], p<0.0001).
CONCLUSIONS
Carriage of the PNPLA3 rs738409 C >G polymorphism is not only associated with greater risk of progressive steatohepatitis and fibrosis but also of HCC. If validated, these findings suggest that PNPLA3 genotyping has the potential to contribute to multi-factorial patient-risk stratification, identifying those to whom HCC surveillance may be targeted.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie |
UniBE Contributor: |
Piguet, Anne Christine, Dufour, Jean-François |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0168-8278 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Lilian Karin Smith-Wirth |
Date Deposited: |
20 Apr 2015 14:31 |
Last Modified: |
05 Dec 2022 14:45 |
Publisher DOI: |
10.1016/j.jhep.2014.02.030 |
PubMed ID: |
24607626 |
Uncontrolled Keywords: |
Gene; HCC; Hepatocellular carcinoma; NAFLD; NASH; PNPLA3; Steatohepatitis |
BORIS DOI: |
10.7892/boris.67130 |
URI: |
https://boris.unibe.ch/id/eprint/67130 |